首页> 美国卫生研究院文献>In Vivo >Drug Delivery Properties of Nanocomposite Particles for Inhalation: Comparison of Drug Concentrations in Lungs and Blood
【2h】

Drug Delivery Properties of Nanocomposite Particles for Inhalation: Comparison of Drug Concentrations in Lungs and Blood

机译:用于吸入的纳米复合颗粒的药物传递特性:肺和血液中药物浓度的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background/Aim: Nanocomposite particles are suitable for inhalation; however, their systemic migration has not been confirmed. The aim of this study was to compare drug concentrations in lungs and blood after inhalation of nanocomposite particles. Materials and Methods: Rifampicin (RFP) was used as a model drug. Nanocomposite particles were prepared from dichloromethane with RFP and poly(DL-lactic acid-co-glycolic acid) (PLGA) dissolved in an amino acid aqueous solution using a spray dryer. Measurement of RFP concentrations in lung and blood of mice was performed by in vivo tests. Results: Compared with the oral administration group as a control, the RFP concentration in the lungs was significantly higher in the inhalation group. In addition, studies with a fluorescent substance suggested sustained release of drugs from nanocomposite particles in the lungs. Conclusion: Nanocomposite particles deliver pulmonary drug in an efficient and sustained manner.
机译:背景/目的:纳米复合颗粒适合吸入。然而,他们的系统迁移尚未得到证实。这项研究的目的是比较吸入纳米复合颗粒后肺和血液中的药物浓度。材料和方法:利福平(RFP)被用作模型药物。使用喷雾干燥器由二氯甲烷和溶解在氨基酸水溶液中的RFP和聚(DL-乳酸-乙醇酸共聚物)(PLGA)制备纳米复合材料颗粒。小鼠肺和血液中RFP浓度的测量通过体内试验进行。结果:与口服对照组相比,吸入组的肺中RFP浓度明显更高。此外,对荧光物质的研究表明,药物从肺中的纳米复合颗粒中持续释放。结论:纳米复合颗粒可有效,持续地递送肺部药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号